A case of Alagille syndrome presenting with chronic cholestasis in an adult

Jihye Kim¹, Bumhee Yang¹, Namyoung Paik¹, Yon Ho Choe², and Yong-Han Paik¹

¹Department of Medicine; ²Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Alagille syndrome (AGS) is a complex multisystem disorder that involves mainly the liver, heart, eyes, face, and skeleton. The main associated clinical features are chronic cholestasis due to a paucity of intrahepatic bile ducts, congenital heart disease primarily affecting pulmonary arteries, vertebral abnormalities, ocular embryotoxon, and peculiar facies. The manifestations generally become evident at a pediatric age. AGS is caused by defects in the Notch signaling pathway due to mutations in JAG1 or NOTCH2. It is inherited in an autosomal dominant pattern with a high degree of penetrance, but variable expressivity results in a wide range of clinical features. Here we report on a 31-year-old male patient who presented with elevated serum alkaline phosphatase and gamma-glutamyl transpeptidase, and was diagnosed with AGS associated with the JAG1 mutation after a comprehensive workup. (Clin Mol Hepatol 2017;23:260-264)

Keywords: Alagille syndrome; Cholestasis; Bile-duct paucity; JAG1; Adult

INTRODUCTION

Alagille syndrome (AGS) is an autosomal-dominant disorder with varying degrees of abnormalities in the liver, heart, eyes, face, bone, and to a lesser degree the kidney, vasculature, and pancreas.¹⁻⁴ The majority of patients with AGS become symptomatic in infancy or early childhood.⁵ A classical diagnosis of AGS has been based on the finding of intrahepatic bile duct paucity on liver biopsy associated with three to five major features: chronic cholestasis, cardiac disease, skeletal abnormalities, ocular abnormalities, and characteristic facial features.¹⁻³

The traditional clinical criteria have been challenged with the emergence of molecular screening, in fact AGS is known to be caused by mutations in one of two genes, namely, JAG1 or NOTCH2.⁶⁻⁷ These genes are part of the Notch signaling pathway, which is involved in cell fate determination. JAG1 mutations have been identified in 70–94% of individuals with clinically diagnosed AGS;⁸⁻¹⁰ while several NOTCH2 mutations have been reported to date.⁷⁻⁸,¹¹ Transmission follows in an autosomal dominant pattern, with a high degree of penetrance but variable expressivity.⁵,¹² In an atypical or mild case, molecular confirmation of the diagnosis of AGS is valuable not only for genetic counseling purposes but also for diagnosis itself.⁹

In this report, we describe the case of AGS diagnosed in one’s adulthood presenting chronic cholestatic feature.
CASE REPORT

A 31-year-old male patient was referred to our center with abnormal liver enzyme level at army physical readiness test 6 months ago. Before coming to our center, he had several tests including liver biopsy, which were insufficient to determine the cause of gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) elevation. He had an unremarkable medical history except receiving surgery due to recurrent left pneumothorax in his teen age. The first laboratory findings at our hospital in February 2013 were as follows: total bilirubin 1.7 mg/dL; aspartate aminotransferase (AST) 78 IU/L; alanine aminotransferase (ALT) 39 IU/L; ALP 308 IU/L; international normalized ratio (INR) 0.88. Immunoglobulin G (IgG) level was within reference range (700-1600 mg/dL). Serum copper as screening test for Wilson’s disease was normal as 129 μg/dL (Reference range: 55-150 μg/dL). Also serum anti-mitochondrial antibodies (AMA) which may be indicative of primary biliary cirrhosis was negative. All the serological markers for viral hepatitis were not remarkable. Liver fibroscan revealed borderline fibrosis with 8.6 kPa and minimal steatosis with controlled attenuation parameter (CAP) level of 227 dB/m. Computed tomography (CT) showed findings consistent with chronic liver disease, without focal nodule or abnormal vascularity (Fig. 1). The result of the first liver biopsy at other tertiary hospital was nonspecific as follows: chronic hepatitis with mild lobular activity, mild periportal activity and septal fibrosis. Our pathologist read that biopsy slide similarly but also noted following findings: rare bile duct in portal tracts.

After three months, liver enzymes showed nonspecific changes: AST slightly increased to 82 IU/L; GGT decreased to 250 IU/L; total bilirubin changed from 1.7 to 2.3 mg/dL. Anti-smooth muscle antibody test showed positive result but at low titer (1:20). Three months later, total bilirubin showed a slight decline but GGT increased to 357 IU/L. Abdominal ultrasonography as follow-up test showed coarse liver parenchymal echotexture without focal hepatic mass or bile duct dilatation is noted. During 10-month follow-up period, ALT increased to 565 IU/L and GGT level remained high. IgG increased steadily to 2011 mg/dL. Se-
The portal triad region shows hepatic arteriole (arrow) and portal venule (star shape) with absence of bile duct. Diffuse lymphocytic infiltration (arrow heads) along portal tract is also seen.

Figure 3. Histologic section of the liver biopsy specimen (H&E, ×200). The portal triad region shows hepatic arteriole (arrow) and portal venule (star shape) with absence of bile duct. Diffuse lymphocytic infiltration (arrow heads) along portal tract is also seen.

Spine radiographs of the patient showed mild hyperostosis of whole spine and also subchondral erosion and sclerosis of both sacroiliac joints. The patient didn’t have any cardiac abnormalities in screening echocardiography. The patient’s father underwent surgery for aortic valve disease in December 2015, but had normal liver function. The other family members – mother and younger sister – had no specific medical history. These three family members didn’t look similar to the patient.

A diagnosis of AGS was made on the combination of the presence of genetic mutation, the result of liver biopsy, characteristic facial features, cholestasis and skeletal abnormalities. We keep on ursodeoxycholic acid therapy and routine check-up with blood test and liver imaging studies.

DISCUSSION

As described above, AGS is a genetic condition that is characterized by chronic cholestasis due to a paucity of bile ducts and multi-organ involvement of varying severity.\(^\text{1,5,12}\) Neonatal cholestasis is a main feature and it can progress to cirrhosis.\(^\text{1,13,14}\) Because the manifestations are predominantly pediatric, a diagnosis of AGS is usually made in early childhood.\(^\text{1}\)

To find the cause of cholestasis is often difficult in clinical practice, especially after ruling out common diseases. In the case presented here, ALT and GGT were dominantly elevated and hyperbilirubinemia was minimal in an adult patient without definite history of hepatobiliary disease. Comprehensive laboratory tests targeting relatively common cholestatic diseases in adult patient were done but the results were negative. A diagnosis of AMA negative primary biliary cirrhosis (PBC) couldn’t be made, because the pathology revealed ductopenia rather than typical bile duct destruction as shown in PBC and the patient had no pruritus, jaundice, dry eye or elevated serum level of immunoglobulin M.\(^\text{16}\) Idiopathic adulthood ductopenia (IAD) is another cholestatic liver disease with biopsy-proven ductopenia. But it isn’t associated with multi-organ involvement including distinguishing facial features. As the term “idiopathic” implies, the etiology of IAD is unknown and a diagnosis of the disease requires exclusion of other conditions with chronic cholestasis.\(^\text{16}\) Most doctors dealing with adult patients are not used to rare syndromic pediatric diseases. That’s why the diagnosis was difficult in this case.

Genetic mutation test was very helpful in confirming the diagnosis of this case. Classically, a diagnosis of AGS was based on the presence of intrahepatic bile duct paucity on liver biopsy with at least three out of five major features: chronic cholestasis, card-
Ac disease, skeletal abnormalities, ocular abnormalities, or dysmorphic facial features. Recently, even a liver biopsy is unnecessary. Because the mutations in JAG1 gene or NOTCH2 play a major role in pathogenesis of the syndrome, whether these mutations exist or not can be a significant feature with clinical symptoms aside. The JAG1 gene is located within band 20p12 and consists of 26 exons that cover 38,000 kb of genomic DNA. The frequency of identifiable genetic mutations in clinically diagnosed AGS patients is high, with JAGGED1 (JAG1) mutations identified in 94% and NOTCH2 mutations in 2% of patients. Though AGS is inherited in an autosomal dominant manner, a substantial portion of AGS is sporadic. In this case, the patient’s family members have no definite features associated with AGS. According to previous reports, approximately 30%-50% of affected individuals have an inherited pathogenic variant and about 50%-70% have a de novo pathogenic variant.

From the medical record, we found that the patient had visited our otology department by himself because of chronic otitis and cholesteatoma in December 2015. The correlation of AGS and chronic otitis has not been established but Quiros-Tejeira’s group reported the high incidence of chronic otitis media in AGS patients. We think chronic otitis can be a manifestation of AGS.

To our knowledge, this is the first report of AGS diagnosed in one’s adulthood. Although the cholestasis was rather mild, the diagnosis was meaningful in terms of predicting prognosis and knowing transmission pattern. Given that the AGS phenotype shows variable expression ranging from mild cholestasis to acute liver failure on cirrhosis, we should think of it as a differential diagnosis for cholestasis with indistinct cause.

**Authors’ contribution**

Conception: Yong-Han Paik

Investigation: Yong-Han Paik, Yon Ho Choe

Data collection: Bumhee Yang, Namyoung Paik

Data curation: Ji hye Kim, Bumhee Yang, Namyoung Paik

Interpretation: Jihye Kim, Yon-Han Paik

Supervision: Yong-Han Paik, Yon Ho Choe

Drafting: Jihye Kim

Review & editing: Yong-Han Paik, Jihye Kim

Critical revision: Yong-Han Paik

Final approval of the version to be published: Yong-Han Paik

**Conflicts of Interest**

The authors have no conflicts to disclose.

**REFERENCES**

1. Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Domergues JP. Syndrome paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987;110:195-200.

2. Depertetere A, Portmann B, Mowat AP. Syndrome paucity of the intrahepatic bile ducts: diagnostic difficulty; severe morbidity throughout early childhood. J Pediatr Gastroenterol Nutr 1987;6:865-871.

3. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999;29:822-829.

4. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243-251.

5. Vajro P, Ferrante L, Paolella G. Alagille syndrome: an overview. Clin Res Hepatol Gastroenterol 2012;36:275-257.

6. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235-242.

7. McDiannii R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet 2006;79:169-173.

8. Cho JM, Oh SH, Kim HJ, Kim JS, Kim KM, Kim GH. Clinical features, outcomes, and genetic analysis in Korean children with Alagille syndrome. Pediatr Int 2015;57:552-527.

9. Warthen DM, Moore EC, Kamath BM, Morissette JJ, Sanchez-Lara PA, Piccoli DA, et al. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate. Hum Mutat 2006;27:436-443.

10. Spinner NB, Colliton RP, Crossner C, Krantz ID, Hadchouel M, Meunier-Rotival M. Jagged1 mutations in Alagille syndrome. Hum Mutat 2001;17:18-33.

11. Lin HC, Le Hoang P, Hutchinson A, Chao G, Gerfen J, Loomes KM, et al. Alagille syndrome in a Vietnamese cohort: mutation analysis and assessment of facial features. Am J Med Genet A 2012;158A:1005-1013.

12. Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012;20:251-257.

13. Hoffenberg EJ, Narkevicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220-224.

14. Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001;49:431-435.

15. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary
biliary cirrhosis. Hepatology 1997;25:1090-1095.
16. Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc 1998;73:285-291.
17. Krantz ID, Colliton RP, Genin A, Rand EB, Li L, Piccoli DA, et al. Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families. Am J Hum Genet 1998;62:1361-1369.
18. Crosnier C, Driancourt C, Raynaud N, Dhome-Pollet S, Pollet N, Bernard O, et al. Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome. Gastroenterology 1999;116:1141-1148.
19. Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr 1999;29:431-437.